MicroPort EP Participates in LAHRS 2023

Mexico City, Mexico, 06 November 2023 — Recently, MicroPort EP made an appearance at the 6th Scientific Session of the Latin American Heart Rhythm Society (LAHRS 2023).

During the conference, MicroPort EP showcased its comprehensive solution for electrophysiological surgical diagnosis and treatment, which included the Columbus 3D EP Navigation System V3 (Columbus™ system V3), along with its accompanying FireMagic TrueForce™ Ablation Catheter (TrueForce™ Ablation Catheter), and other products in the series.

The booth at the event attracted experts from countries and regions such as Brazil, Mexico, Argentina, Venezuela, and Ecuador, who were able to experience the performance of the products. Dr. Nestor Hugo Lopez Cabanillas, the Vice President of LAHRS and an Argentine physician, also visited the booth and exchanged views on MicroPort EP’s latest products and technological applications.

This exhibition marked the debut of the Columbus system V3 in the Latin American market. Electrophysiology experts viewed demonstration videos showcasing its magnetic and impedance-based positioning function. They also engaged in discussions about the newly CE-certified TrueForce™ Ablation Catheter and expressed their anticipation for MicroPort EP’s forthcoming product offering.

So far, MicroPort EP’s products have been exported to more than thirty countries and regions. Moving forward, MicroPort EP will actively expand its global market presence by providing patients and doctors with more comprehensive products and professional services, offering globally competitive integrated solutions for electrophysiological interventions and treatments.

About MicroPort EP

Founded in 2010, MicroPort EP (Shanghai MicroPort EP MedTech Co., Ltd; SSE: 688351), an associated company of MicroPort® (MicroPort Scientific Corporation; HKEX: 00853), is a global medical devices company focusing on the development, manufacturing, and commercializing minimally invasive medical devices for the treatment of cardiac arrhythmia. It has developed a family of advanced cardiac ablation catheters, diagnostic catheters, and 3D navigation systems. These solutions are used by hundreds of physicians at over 1200 hospitals over more than 30 countries. At MicroPort EP, we strive to provide integrated therapeutic solutions to apply precise navigation on interventional procedures, dedicated to providing high quality therapeutic solutions to patients and physicians across the globe.

More information is available at www.everpace.com/en